EAACI Congress 2025
BackL-TPS02 - Asthma 09
Friday 13 Jun, 12:00 PM -
13:00 PM Glasgow, United Kingdom
Poster Zone
Thematic Poster Session
Anti-Inflammatory Effects of miRNA-Mediated Extracellular Vesicles Derived from Mesenchymal Stem Cells in a Murine Asthma Model
Associations between Serum Clara Cell Protein 16 (CC16) and Asthma Severity in Children
Biological therapy in severe asthma: 20 years of experience at the Hospital Universitario de Burgos
Bispecific Antibody Targeting IL-33 and TSLP for Treating Asthma and COPD
Combing dual biologics therapy for severe asthma : a series of ten cases
Deciphering Genetic Causal Relationships and Molecular Mechanisms Linking Multiple Allergic Diseases and Schizophrenia
Distinct roles of Natural killer T Cells and Innate Lymphoid Cells in Type I and II airway Inflammation Induced by Viral Infection
Dupilumab in a Child with Severe Allergic Asthma, Atopic Dermatitis, Vernal Keratoconjunctivitis, and Partial IgA Deficiency
Hydrogen peroxide in exhaled breath condensate as a marker for monitoring biologic treatment response in severe asthmatic patients
Identifying Genetic Factors Regulating Human IgE-Mediated Reactions Using Whole Genome Sequencing
Inhibition of the Interleukin Cytokines using novel Peptide Inhibitors for Allergy and Asthma Treatment
Predictive Factors of Clinical Remission in Severe Eosinophilic Asthma Treated with Benralizumab
Severe Airflow Limitation Unmasked by NSAID Hypersensitivity: A Case of Undiagnosed Persistent Asthma with Nasal Polyposis
TRough levels In plasma of dUpilumab and Mepolizumab in Patients with severe astHma (TRIUMPH)
The Use of Long-Acting Muscarinic Antagonist in the Treatment of Asthma: A Latin-American 2 Specialized Asthma Center Experience
